Charles River Laboratories Inter (NYSE: CRL) has reported E.P.S. of $1.70 for its third fiscal quarter (ending September 30) versus $1.90 for the same period a year ago — a decline of -11%. Relative to the consensus estimate of $2.37, this was a shortfall of $-0.67. For the latest four quarters through September 30, E.P.S. were $9.30 compared to $8.61 a year ago — an increase of 8%.
Recent Price Action
Charles River Laboratories Inter (NYSE: CRL) stock closed at $175.97 on 11/8/23 after a large decline of -3.7%. The stock has risen 4.5% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, CRL is expected to continue to be an important Value Builder.
Charles River Laboratories Inter has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects consistent signals from PTR's two proprietary measures of a stock's attractiveness. Charles River Laboratories Inter has a neutral Appreciation Score of 56 and a slightly negative Power Rating of 40, and the Low Neutral Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.